News
CARLSBAD, Calif.--(BUSINESS WIRE)--Encore Therapeutics Inc. (ETI) has developed a proprietary extended release subcutaneous (SC) depot formulation (ETI-511) of the NSAID drug meloxicam.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback